Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix). (28th January 2017)
- Record Type:
- Journal Article
- Title:
- Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix). (28th January 2017)
- Main Title:
- Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)
- Authors:
- Guardo, Alberto C.
Joe, Patrick Tjok
Miralles, Laia
Bargalló, Manel E.
Mothe, Beatriz
Krasniqi, Ahmet
Heirman, Carlo
García, Felipe
Thielemans, Kris
Brander, Christian
Aerts, Joeri L.
Plana, Montserrat - Abstract:
- Abstract : Background: The development of a prophylactic vaccine against HIV-1 has so far not been successful. Therefore, attention has shifted more and more toward the development of novel therapeutic vaccines. Here, we evaluated a new mRNA-based therapeutic vaccine against HIV-1-encoding activation signals (TriMix: CD40L + CD70 + caTLR4) combined with rationally selected antigenic sequences [HIVACAT T-cell immunogen (HTI)] sequence: comprises 16 joined fragments from Gag, Pol, Vif, and Nef). Methods: For this purpose, peripheral blood mononuclear cells from HIV-1-infected individuals on cART, lymph node explants from noninfected humans, and splenocytes from immunized mice were collected and several immune functions were measured. Results: Electroporation of immature monocyte-derived dendritic cells from HIV-infected patients with mRNA encoding HTI + TriMix potently activated dendritic cells which resulted in upregulation of maturation markers and cytokine production and T-cell stimulation, as evidenced by enhanced proliferation and cytokine secretion (IFN-γ). Responses were HIV specific and were predominantly targeted against the sequences included in HTI. These findings were confirmed in human lymph node explants exposed to HTI + TriMix mRNA. Intranodal immunizations with HTI mRNA in a mouse model increased antigen-specific cytotoxic T-lymphocyte responses. The addition of TriMix further enhanced cytotoxic responses. Conclusion: Our results suggest that uptake of mRNA,Abstract : Background: The development of a prophylactic vaccine against HIV-1 has so far not been successful. Therefore, attention has shifted more and more toward the development of novel therapeutic vaccines. Here, we evaluated a new mRNA-based therapeutic vaccine against HIV-1-encoding activation signals (TriMix: CD40L + CD70 + caTLR4) combined with rationally selected antigenic sequences [HIVACAT T-cell immunogen (HTI)] sequence: comprises 16 joined fragments from Gag, Pol, Vif, and Nef). Methods: For this purpose, peripheral blood mononuclear cells from HIV-1-infected individuals on cART, lymph node explants from noninfected humans, and splenocytes from immunized mice were collected and several immune functions were measured. Results: Electroporation of immature monocyte-derived dendritic cells from HIV-infected patients with mRNA encoding HTI + TriMix potently activated dendritic cells which resulted in upregulation of maturation markers and cytokine production and T-cell stimulation, as evidenced by enhanced proliferation and cytokine secretion (IFN-γ). Responses were HIV specific and were predominantly targeted against the sequences included in HTI. These findings were confirmed in human lymph node explants exposed to HTI + TriMix mRNA. Intranodal immunizations with HTI mRNA in a mouse model increased antigen-specific cytotoxic T-lymphocyte responses. The addition of TriMix further enhanced cytotoxic responses. Conclusion: Our results suggest that uptake of mRNA, encoding strong activation signals and a potent HIV antigen, confers a T-cell stimulatory capacity to dendritic cells and enhances their ability to stimulate antigen-specific immunity. These findings may pave the way for therapeutic HIV vaccine strategies based on antigen-encoding RNA to specifically target antigen-presenting cells. Abstract : Supplemental Digital Content is available in the text … (more)
- Is Part Of:
- AIDS. Volume 31:Number 3(2017)
- Journal:
- AIDS
- Issue:
- Volume 31:Number 3(2017)
- Issue Display:
- Volume 31, Issue 3 (2017)
- Year:
- 2017
- Volume:
- 31
- Issue:
- 3
- Issue Sort Value:
- 2017-0031-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2017-01-28
- Subjects:
- HIV vaccines -- HTI -- mRNA electroporation
AIDS (Disease) -- Periodicals
Acquired Immunodeficiency Syndrome
AIDS (Disease)
Periodicals
Periodicals
616.9792005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&PAGE=toc&D=ovft&AN=00002030-000000000-00000 ↗
http://journals.lww.com/aidsonline/pages/default.aspx?desktopMode=true ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1097/QAD.0000000000001276 ↗
- Languages:
- English
- ISSNs:
- 0269-9370
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0773.083000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 8039.xml